{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:57Z","timestamp":1786987497451,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.critrevonc.2013.10.005","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T03:00:44Z","timestamp":1381546844000},"page":"242-247","source":"Crossref","is-referenced-by-count":39,"title":["Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?"],"prefix":"10.1016","volume":"89","author":[{"given":"Semra","family":"Paydas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2013.10.005_bib0005","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0010","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a maj\u00f6r target of the Bcr-Abl inhibit\u00f6r dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0015","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0020","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0025","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","article-title":"Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia","volume":"40","author":"Kreutzman","year":"2012","journal-title":"Exper Hematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0030","doi-asserted-by":"crossref","first-page":"21452152","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/leu.2008.273","article-title":"Does chemotherapy modify the immune surveillance of hematological malignancies","volume":"23","author":"Barrett","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0040","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","article-title":"The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro","volume":"127","author":"Blake","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0045","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0050","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","article-title":"Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion","volume":"91","author":"Nagata","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.abb.2011.02.009","article-title":"Protein tyrosine kinases in neutrophil activation and recruitment","volume":"510","author":"Zarbock","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0065","first-page":"194","article-title":"A sharp fluctuation in peripheral blood cells shortly after dasatinib administration","volume":"96","author":"Imagawa","year":"2012","journal-title":"In J Hematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0070","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukaemia in chronic phase and efficacy is uneffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0080","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukaemia","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0090","article-title":"Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myeloid leukaemia patients","author":"Tanaka","year":"2012","journal-title":"In J Hematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.21980","article-title":"Retrospective multicenter study on the development on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukaemia","volume":"86","author":"Lee","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0105","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonla T and NK cells are common in chronic myeloid leukaemia patients and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0110","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.leukres.2010.08.022","article-title":"Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML)","volume":"35","author":"Valent","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0120","first-page":"181","article-title":"Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib","volume":"51","author":"Hoshino","year":"2010","journal-title":"Rinsho Ketsueki."},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0125","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood.V87.6.2476.bloodjournal8762476","article-title":"Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture","volume":"87","author":"Cervantes","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.1996.4991043.x","article-title":"Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukemia and their role in the in vitro disappearance of BCR\/ABL-positive targets","volume":"93","author":"Silla","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0135","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/1521-4141(200203)32:3<773::AID-IMMU773>3.0.CO;2-U","article-title":"A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors","volume":"32","author":"Lowin-kropf","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20050449","article-title":"Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn","volume":"202","author":"Bloch-Queyrat","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/cimm.1995.1207","article-title":"Phosphorylation of src family tyrosine kinase following interleukin-12 activation of human natural killer cells","volume":"165","author":"Pignata","year":"1995","journal-title":"Cell Immunol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0150","doi-asserted-by":"crossref","first-page":"16415","DOI":"10.1074\/jbc.270.27.16415","article-title":"Interaction between lck and syk family tyrosine kinases in Fc gamma receptor-initiated activation of natural killer cells","volume":"270","author":"Ting","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0155","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1084\/jem.190.8.1189","article-title":"The Src family tyrosine kinase Fyn regulates natural killer T cell development","volume":"190","author":"Gadue","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0160","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen- specific T-cell effector functions by dasatinib","volume":"14","author":"Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0170","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/10428194.2010.550074","article-title":"A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors","volume":"52","author":"Powers","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0175","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0180","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2005-02-0479","article-title":"The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target cell interactions","volume":"106","author":"Sconocchia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0185","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Crit Care Med"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0190","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cncr.24155","article-title":"Dasatinib treatment for Philadelphia chromosome positive leukemias","volume":"115","author":"Khoury","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0195","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Dasatinib 50mg or 70mg BID compared to 100mg or 140mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034 (abs)","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0200","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myeloid leukemia treated ith dasatinib after imatinib failure","volume":"25","author":"Quint\u00e2s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0205","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immun-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0210","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0215","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.bor.0000240353.99808.5f","article-title":"B cell receptor signaling in human systemic lupus erythematosus","volume":"18","author":"Pugh-Bernard","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.critrevonc.2013.10.005_bib0220","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/art.10978","article-title":"Increased ubiquination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus","volume":"48","author":"Jury","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813002151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813002151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T18:03:29Z","timestamp":1596650609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813002151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1040842813002151"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.10.005","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}